查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1363090

細胞株開發市場規模、佔有率、趨勢分析報告：按產品/服務、按原料、按細胞株類型、按用途、細分趨勢，2023-2030

Cell Line Development Market Size, Share & Trends Analysis Report By Product & Services (Reagents And Media, Equipment), By Source (Mammalian, Non-mammalian), By Type of Cell Line, By Source, By Application, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10個工作天內

價格

細胞株開發市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球細胞株開發市場規模將達到100.9億美元，2023年至2030年年複合成長率為9.81%。

推動細胞株開發（CLD）市場擴大的主要要素之一是全球疫苗產量的增加，特別是在冠狀病毒傳播之後。新醫療保健技術的日益普及和癌症罹患率的上升為 CLD 市場創造了更具吸引力和有利的成長預測。生技藥品領域的擴張和成長也預計將成為 CLD 市場開拓的關鍵決定要素。

市場上越來越多的技術改進的 CLD 治療方法預計也將推動市場擴張。例如，BICO 子公司 CYTENA 於 2021 年 10 月宣布推出全自動、穩定細胞株開發的新平台。為了提高成本效益並實現更高的實驗室自動化，該系統整合CYTENA 一流的液體處理資訊與現有和成熟的單細胞分液技術整合在一起。 BICO 的生物融合議程是透過擴大抗體療法、基因療法和生物相似藥製造等下一代醫療服務開發的可及性來推動的。

此外，根據 2021 年 7 月的《藥品製造更新》，大約 20 種藥物預計將於 2023 年專利到期，其中包括諾華 (Novartis) 的 Entresto 和百健 (Biogen) 的 Spinraza 等多種重磅藥物。原廠藥專利到期催生了生物相似藥的誕生。因此，對細胞株開發的需求不斷增加。因此，預計它將成為市場成長的驅動力。

此外，聯盟、擴張和收購等不斷發展的企業策略也推動了市場的成長。例如，ProBioGen 和 Granite Bio 於 2022 年 7 月合作，提供 GMP 製造和細胞株開發解決方案，並支援 Granite Bio 的 mAb 管道開發。同樣，2022年6月，FUJIFILM公司宣布將投資16億美元，用於改善和擴大FUJIFILM Diosynth Biotechnologies的細胞培養產能。此外，2022 年 10 月，Cytiva收購了CEVEC Pharmaceuticals，這是一家先進的 CLD 和病毒載體製造技術的德國著名製造商。透過此次開發，CEVEC將幫助Cytiva保持在生物製造技術領域的領先地位。

然而，建立研發能力所需的高資本成本和支出可能成為細胞株開發產業的障礙。

細胞株開發市場報告亮點

  • 依按產品，試劑和培養基板塊佔比最大，2022年佔43.78%。由於其成本集中和在生技藥品生產中的頻繁使用，這些產品佔據了收益佔有率。
  • 它的快速擴張是哺乳動物細胞株有效生產生物製藥的結果，因為它們可以表達與人類相同的複雜蛋白質。
  • 依細胞株類型分類，重組細胞株公司細分市場佔比最大，2022年佔比為31.79%。這是由於它在生技藥品製造流程、基因活化、蛋白質相互作用等方面的廣泛應用。
  • 從用途來看，生物生產領域佔比最大，2022年將達46.30%。體外研究活動的增加、對產品安全性和功效的擔憂、對生物相似藥的需求以及對細胞療法的需求不斷成長要素正在推動生物生產行業的發展。
  • 2022 年，北美佔據了 39.22% 的較大佔有率，因為不斷的技術改進和隨後的新發現引發了生物生產新製程的採用。該地區提供高品質 CLD 服務的研究公司的嚴格活動推動了成長，這些公司包括 Thermo Fisher Scientific Inc.、Sigma-Aldrich Corporation 和美國典型培養物保藏中心 (ATCC)。
  • 市場的主要參與者包括 Thermo Fisher Scientific Inc.、Corning Inc.、Lonza、Creative BioLabs.、WuXi PharmaTech、Sartorius AG、Merck KGaA、Advanced Instruments、Berkeley Lights 和 Danaher。

目錄

第1章 調查方法和範圍

第2章 執行摘要

第3章 市場變數、趨勢和範圍

  • 市場體系預測
    • 母市場預測
    • 相關/附隨市場預測
  • 市場趨勢及展望
  • 市場動態
    • 重磅生技藥品專利到期
    • 對單株抗體的需求不斷成長
    • 疫苗產量增加
    • 細胞株開發的技術進步
    • 癌症罹患率增加
    • 加大生物科技領域研發投入
  • 市場抑制因素分析
    • 存在複雜的法規結構
  • 營商環境分析
    • PESTEL分析
    • 波特五力分析
    • COVID-19感染疾病的影響分析

第4章 按產品/服務分類的業務分析

  • 全球細胞株開發市場：產品與服務的波動分析
  • 試劑和介質
  • 裝置
    • 自動化系統
    • 離心機
    • 生物反應器
    • 倉儲設備
    • 其他
  • 配件及消耗品
  • 服務

第5章 按來源分類的業務分析

  • 全球細胞株開發市場：來源變異分析
  • 哺乳動物細胞株
  • 非哺乳動物細胞株

第6章 按細胞株類型進行業務分析

  • 全球細胞株開發市場：細胞株類型變化分析
  • 重組細胞株
  • 雜交瘤
  • 連續性細胞株
  • 原代細胞株

第7章 用途業務分析

  • 全球細胞株開發市場：依用途進行變異分析
  • 生物生產
  • 藥物研發
  • 毒性試驗
  • 組織工程
  • 其他

第8章 區域業務分析

  • 2022年及2030年全球細胞株開發市場佔有率（按地區）
  • 北美洲
    • 北美細胞株開發市場，2018-2030
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲細胞株開發市場，2018-2030
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 亞太細胞株開發市場，2018-2030
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 拉丁美洲細胞株開發市場，2018-2030
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • MEA細胞株開發市場，2018-2030
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭形勢

  • 公司分類
  • 策略規劃
  • Company Market/PositionShare Analysis, 2022
  • 公司簡介/名單
    • Thermo Fisher Scientific Inc.
    • Danaher
    • Merck KGaA
    • Sartorius AG
    • Lonza
    • WuXi PharmaTech
    • Advanced Instruments
    • Berkeley Lights
    • Creative BioLabs
    • Corning Inc.
Product Code: 978-1-68038-481-9

Cell Line Development Market Growth & Trends:

The global cell line development market size is expected to reach USD 10.09 billion by 2030 and is expected to expand at a CAGR of 9.81% from 2023 to 2030, according to a new report by Grand View Research, Inc.. One of the primary factors driving the expansion of the cell line development (CLD) market is an increase in vaccine production around the world, especially after the spread of coronavirus. Rising use of new healthcare technology and rising cancer incidences, create more attractive and lucrative growth prospects for the CLD market. The expansion and growth of the biologics sector will also be a major CLD market development determinant.

The increasing product launches of technologically improved products for CLD are likely to drive market expansion. For example, CYTENA, a BICO subsidiary, introduced a new platform for entirely automated stable cell line development in October 2021. To enable cost-effective and better laboratory automation, the system integrates CYTENA's best-in-class liquid handling information with its existing established single-cell dispensing technology. BICO's Bio Convergence agenda is advanced through the broadening of accessibility to the advancement of next-generation medical services such as antibody treatments, gene therapies, and biosimilar production.

Moreover, according to the July 2021 Pharma Manufacturing Updates, approximately 20 drugs, comprising a few blockbusters including Novartis' Entresto & Biogen's Spinraza, are going to have their patents scheduled to expire in 2023. The expiration of branded pharmaceuticals has resulted in the creation of biosimilars. As a result, the requirement for cell line development is increasing. Thus, it will drive the market growth.

Furthermore, the growing company strategies such as collaboration, expansion, and acquisitions are also driving the market growth. For instance, ProBioGen and Granite Bio collaborated in July 2022 to provide GMP manufacturing & cell line development solutions and support Granite Bio's mAb pipeline development. Similarly, in June 2022, FUJIFILM Corporation announced a USD 1.6 billion investment to improve and expand the cell culture production capabilities of FUJIFILM Diosynth Biotechnologies. Furthermore, in October 2022, Cytiva, acquired CEVEC Pharmaceuticals, a prominent German producer of advanced CLD & viral vector manufacturing technology. Through this development, CEVEC will help Cytiva maintain its leadership position in biomanufacturing technologies.

However, the high capital expenses and expenditure needed to construct research and development capabilities would be a barrier to the cell line development industry.

Cell Line Development Market Report Highlights:

  • By product, the reagents and media segment accounted for the largest share of 43.78% in 2022. Due to their cost-intensive nature and frequent use in the manufacturing of biologics, these items account for the biggest revenue share.
  • By source, the mammalian cell line segment accounted for the largest share of 72.62% in 2022.Its rapid expansion is a result of the effective manufacture of biopharmaceuticals by mammalian cell lines, as they are able to express complex proteins that are identical to those found in humans.
  • By type of cell line, the recombinant cell lines companies segment accounted for the largest share of 31.79% in 2022 due to its widespread application in biologics manufacturing processes, gene activation, including protein interactions.
  • By application, the bioproduction segment held the largest market share of 46.30% in 2022. Factors such as increased in-vitro research activities, product safety and efficacy concerns, the demand for biosimilars, and rising demand for cellular therapies are driving the bioproduction industry.
  • North America held the larger share of 39.22% in 2022 due to the presence of constant technological improvements followed by new discoveries sparking the adoption of newer processes for bioproduction. The presence of rigorous activities carried out by research businesses operating in this region, such as Thermo Fisher Scientific Inc., Sigma-Aldrich Corporation, and American Type Culture Collection (ATCC), which provide high-quality CLD services, is contributing to growth.
  • A few of the key market players of the market include Thermo Fisher Scientific Inc., Corning Inc., Lonza, Creative BioLabs., WuXi PharmaTech, Sartorius AG, Merck KGaA, Advanced Instruments, Berkeley Lights, Danaher among others.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Information analysis
    • 1.2.2. Market formulation & data visualization
    • 1.2.3. Data validation & publishing
  • 1.3. Information Procurement
    • 1.3.1. Primary Others
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Market Model
  • 1.7. Objectives
    • 1.7.1. Objective 1
    • 1.7.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Patent expiration of blockbuster biologics
    • 3.3.2. Rising demand for monoclonal antibodies
    • 3.3.3. Increasing vaccine production
    • 3.3.4. Technological advancement for the cell line development
    • 3.3.5. Increasing prevalence of cancer
    • 3.3.6. Growing R&D investments in biotechnology sector
  • 3.4. Market Restraint Analysis
    • 3.4.1. Presence of complicated regulatory framework
  • 3.5. Business Environment Analysis
    • 3.5.1. PESTEL Analysis
    • 3.5.2. Porter's Five Forces Analysis
    • 3.5.3. COVID-19 Impact Analysis

Chapter 4. Product & Services Business Analysis

  • 4.1. Global cell line development market: Product & Services Movement Analysis
  • 4.2. Reagents and media
    • 4.2.1. Reagents and media Market, 2018 - 2030 (USD Million)
  • 4.3. Equipment
    • 4.3.1. Equipment Market, 2018 - 2030 (USD Million)
    • 4.3.2. Automated Systems
      • 4.3.2.1. Automated Systems Market, 2018 - 2030 (USD Million)
    • 4.3.3. Centrifuges
      • 4.3.3.1. Centrifuges Market, 2018 - 2030 (USD Million)
    • 4.3.4. Bioreactors
      • 4.3.4.1. Bioreactors Market, 2018 - 2030 (USD Million)
    • 4.3.5. Storage equipment
      • 4.3.5.1. Storage equipment Market, 2018 - 2030 (USD Million)
    • 4.3.6. Others
      • 4.3.6.1. Others Market, 2018 - 2030 (USD Million)
  • 4.4. Accessories and consumables
    • 4.4.1. Accessories and consumables Market, 2018 - 2030 (USD Million)
  • 4.5. Services
    • 4.5.1. Services Market, 2018 - 2030 (USD Million)

Chapter 5. Source Business Analysis

  • 5.1. Global cell line development market: Source Movement Analysis
  • 5.2. Mammalian cell line
    • 5.2.1. Mammalian cell line Market, 2018 - 2030 (USD Million)
  • 5.3. Non-mammalian cell line
    • 5.3.1. Non-mammalian cell line Market, 2018 - 2030 (USD Million)
    • 5.3.2. Insects
      • 5.3.2.1. Insects Market, 2018 - 2030 (USD Million)
    • 5.3.3. Amphibians
      • 5.3.3.1. Amphibians Market, 2018 - 2030 (USD Million)

Chapter 6. Type of Cell Lines Business Analysis

  • 6.1. Global cell line development market: Type of Cell Lines Movement Analysis
  • 6.2. Recombinant cell lines
    • 6.2.1. Recombinant cell lines Market, 2018 - 2030 (USD Million)
  • 6.3. Hybridomas
    • 6.3.1. Hybridomas Market, 2018 - 2030 (USD Million)
  • 6.4. Continuous cell lines
    • 6.4.1. Continuous cell lines Market, 2018 - 2030 (USD Million)
  • 6.5. Primary cell lines
    • 6.5.1. Primary cell lines Market, 2018 - 2030 (USD Million)

Chapter 7. Application Business Analysis

  • 7.1. Global cell line development market: Application Movement Analysis
  • 7.2. Bioproduction
    • 7.2.1. Bioproduction Market, 2018 - 2030 (USD Million)
  • 7.3. Drug discovery
    • 7.3.1. Drug discovery Market, 2018 - 2030 (USD Million)
  • 7.4. Toxicity testing
    • 7.4.1. Toxicity testing Market, 2018 - 2030 (USD Million)
  • 7.5. Tissue engineering
    • 7.5.1. Tissue engineering Market, 2018 - 2030 (USD Million)
  • 7.6. Others
    • 7.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Regional Business Analysis

  • 8.1. Global Cell line development market Share By Region, 2022 & 2030
  • 8.2. North America
    • 8.2.1. North America cell line development market, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. Competitive Scenario
      • 8.2.2.3. Regulatory Framework
      • 8.2.2.4. Target Disease Prevalence
      • 8.2.2.5. U.S. cell line development market, 2018 - 2030 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Competitive Scenario
      • 8.2.3.3. Regulatory Framework
      • 8.2.3.4. Target Disease Prevalence
      • 8.2.3.5. Canada cell line development market, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe Cell line development market, 2018 - 2030 (USD Million)
    • 8.3.2. Germany
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Competitive Scenario
      • 8.3.2.3. Regulatory Framework
      • 8.3.2.4. Target Disease Prevalence
      • 8.3.2.5. Germany cell line development market, 2018 - 2030 (USD Million)
    • 8.3.3. UK
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Competitive Scenario
      • 8.3.3.3. Regulatory Framework
      • 8.3.3.4. Target Disease Prevalence
      • 8.3.3.5. UK cell line development market, 2018 - 2030 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Competitive Scenario
      • 8.3.4.3. Regulatory Framework
      • 8.3.4.4. Target Disease Prevalence
      • 8.3.4.5. France cell line development market, 2018 - 2030 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Competitive Scenario
      • 8.3.5.3. Regulatory Framework
      • 8.3.5.4. Target Disease Prevalence
      • 8.3.5.5. Italy cell line development market, 2018 - 2030 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Competitive Scenario
      • 8.3.6.3. Regulatory Framework
      • 8.3.6.4. Target Disease Prevalence
      • 8.3.6.5. Spain cell line development market, 2018 - 2030 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Competitive Scenario
      • 8.3.7.3. Regulatory Framework
      • 8.3.7.4. Target Disease Prevalence
      • 8.3.7.5. Denmark cell line development market, 2018 - 2030 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Competitive Scenario
      • 8.3.8.3. Regulatory Framework
      • 8.3.8.4. Target Disease Prevalence
      • 8.3.8.5. Sweden cell line development market, 2018 - 2030 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Competitive Scenario
      • 8.3.9.3. Regulatory Framework
      • 8.3.9.4. Target Disease Prevalence
      • 8.3.9.5. Norway cell line development market, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific cell line development market, 2018 - 2030 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Target Disease Prevalence
      • 8.4.2.5. Japan cell line development market, 2018 - 2030 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Target Disease Prevalence
      • 8.4.3.5. China cell line development market, 2018 - 2030 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Target Disease Prevalence
      • 8.4.4.5. India cell line development market, 2018 - 2030 (USD Million)
    • 8.4.5. South Korea
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Competitive Scenario
      • 8.4.5.3. Regulatory Framework
      • 8.4.5.4. Target Disease Prevalence
      • 8.4.5.5. South Korea cell line development market, 2018 - 2030 (USD Million)
    • 8.4.6. Australia
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Competitive Scenario
      • 8.4.6.3. Regulatory Framework
      • 8.4.6.4. Target Disease Prevalence
      • 8.4.6.5. Australia cell line development market, 2018 - 2030 (USD Million)
    • 8.4.7. Thailand
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Competitive Scenario
      • 8.4.7.3. Regulatory Framework
      • 8.4.7.4. Target Disease Prevalence
      • 8.4.7.5. Thailand cell line development market, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America cell line development market, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Target Disease Prevalence
      • 8.5.2.5. Brazil cell line development market, 2018 - 2030 (USD Million)
    • 8.5.3. Mexico
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Target Disease Prevalence
      • 8.5.3.5. Mexico cell line development market, 2018 - 2030 (USD Million)
    • 8.5.4. Argentina
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Target Disease Prevalence
      • 8.5.4.5. Argentina cell line development market, 2018 - 2030 (USD Million)
  • 8.6. MEA
    • 8.6.1. MEA cell line development market, 2018 - 2030 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Target Disease Prevalence
      • 8.6.2.5. South Africa cell line development market, 2018 - 2030 (USD Million)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Target Disease Prevalence
      • 8.6.3.5. Saudi Arabia cell line development market, 2018 - 2030 (USD Million)
    • 8.6.4. UAE
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Target Disease Prevalence
      • 8.6.4.5. UAE cell line development market, 2018 - 2030 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Target Disease Prevalence
      • 8.6.5.5. Kuwait cell line development market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Market/PositionShare Analysis, 2022
  • 9.4. Company Profiles/Listing
    • 9.4.1. Thermo Fisher Scientific Inc.
      • 9.4.1.1. Overview
      • 9.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Strategic Initiatives
    • 9.4.2. Danaher
      • 9.4.2.1. Overview
      • 9.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Strategic Initiatives
    • 9.4.3. Merck KGaA
      • 9.4.3.1. Overview
      • 9.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Strategic Initiatives
    • 9.4.4. Sartorius AG
      • 9.4.4.1. Overview
      • 9.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Strategic Initiatives
    • 9.4.5. Lonza
      • 9.4.5.1. Overview
      • 9.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Strategic Initiatives
    • 9.4.6. WuXi PharmaTech
      • 9.4.6.1. Overview
      • 9.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Strategic Initiatives
    • 9.4.7. Advanced Instruments
      • 9.4.7.1. Overview
      • 9.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Strategic Initiatives
    • 9.4.8. Berkeley Lights
      • 9.4.8.1. Overview
      • 9.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Strategic Initiatives
    • 9.4.9. Creative BioLabs
      • 9.4.9.1. Overview
      • 9.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Strategic Initiatives
    • 9.4.10. Corning Inc.
      • 9.4.10.1. Overview
      • 9.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviations
  • Table 3 Global Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 4 Global Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 5 Global Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 6 Global Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 7 North America Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 8 North America Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 9 North America Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 10 North America Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 11 North America Cell line development market by Country, 2018 - 2030 (USD Million)
  • Table 12 U.S. Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 13 U.S. Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 14 U.S. Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 15 U.S. Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 16 Canada Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 17 Canada Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 18 Canada Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 19 Canada Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 20 Europe Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 21 Europe Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 22 Europe Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 23 Europe Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 24 Europe Cell line development market by Country, 2018 - 2030 (USD Million)
  • Table 25 UK Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 26 UK Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 27 UK Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 28 UK Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 29 Germany Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 30 Germany Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 31 Germany Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 32 Germany Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 33 France Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 34 France Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 35 France Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 36 France Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 37 Italy Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 38 Italy Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 39 Italy Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 40 Italy Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 41 Spain Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 42 Spain Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 43 Spain Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 44 Spain Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 45 Denmark Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 46 Denmark Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 47 Denmark Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 48 Denmark Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 49 Sweden Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 50 Sweden Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 51 Sweden Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 52 Sweden Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 53 Norway Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 54 Norway Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 55 Norway Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 56 Norway Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 61 Asia Pacific Cell line development market by Country, 2018 - 2030 (USD Million)
  • Table 62 China Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 63 China Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 64 China Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 65 China Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 66 Japan Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 67 Japan Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 68 Japan Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 69 Japan Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 70 India Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 71 India Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 72 India Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 73 India Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 74 South Korea Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 75 South Korea Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 76 South Korea Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 77 South Korea Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 78 Australia Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 79 Australia Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 80 Australia Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 81 Australia Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 82 Thailand Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 83 Thailand Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 84 Thailand Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 85 Thailand Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 86 Latin America Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 87 Latin America Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 88 Latin America Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 89 Latin America Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 90 Latin America Cell line development market by Country, 2018 - 2030 (USD Million)
  • Table 91 Brazil Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 92 Brazil Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 93 Brazil Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 94 Brazil Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 95 Mexico Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 96 Mexico Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 97 Mexico Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 98 Mexico Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 99 Argentina Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 100 Argentina Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 101 Argentina Cell line development market by Type of Cell Liner, 2018 - 2030 (USD Million)
  • Table 102 Argentina Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 103 Middle East & Africa Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 107 Middle East & Africa Cell line development market by Country, 2018 - 2030 (USD Million)
  • Table 108 South Africa Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 109 South Africa Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 110 South Africa Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 111 South Africa Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 112 Saudi Arabia Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 116 UAE Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 117 UAE Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 118 UAE Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 119 UAE Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 120 Kuwait Cell line development market by Product & Services, 2018 - 2030 (USD Million)
  • Table 121 Kuwait Cell line development market by Source, 2018 - 2030 (USD Million)
  • Table 122 Kuwait Cell line development market By Type of Cell Line, 2018 - 2030 (USD Million)
  • Table 123 Kuwait Cell line development market by Application, 2018 - 2030 (USD Million)
  • Table 124 Participant's Overview
  • Table 125 Financial Performance
  • Table 126 Key Companies Undergoing Expansions
  • Table 127 Key Companies Undergoing Acquisitions
  • Table 128 Key Companies Undergoing Collaborations
  • Table 129 Key Companies Launching New Products/Services
  • Table 130 Key Companies Undergoing Partnerships
  • Table 131 Key Companies Undertaking Other Strategies

List of Figures

  • Fig. 1 Market Others process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary Others pattern
  • Fig. 4 Market Others approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market summary, 2022 (USD Million)
  • Fig. 9 Market segmentation & scope
  • Fig. 10 Market driver impact
  • Fig. 11 Market restraint impact
  • Fig. 12 Penetration & growth prospect mapping
  • Fig. 13 Porter's analysis
  • Fig. 14 SWOT analysis
  • Fig. 15 Global cell line development market: Product & services outlook and key takeaways
  • Fig. 16 Global cell line development market: Product & services movement analysis
  • Fig. 17 Global reagents and media market, 2018 - 2030 (USD Million)
  • Fig. 18 Global equipment market, 2018 - 2030 (USD Million)
  • Fig. 19 Global Automated Systems market, 2018 - 2030 (USD Million)
  • Fig. 20 Global centrifuges market, 2018 - 2030 (USD Million)
  • Fig. 21 Global bioreactors market, 2018 - 2030 (USD Million)
  • Fig. 22 Global storage equipment market, 2018 - 2030 (USD Million)
  • Fig. 23 Global Others market, 2018 - 2030 (USD Million)
  • Fig. 24 Global Accessories and consumables market, 2018 - 2030 (USD Million)
  • Fig. 25 Global cell line development market: Source outlook and key takeaways
  • Fig. 26 Global cell line development market: Source movement analysis
  • Fig. 27 Global mammalian cell line market, 2018 - 2030 (USD Million)
  • Fig. 28 Global non-mammalian cell line market, 2018 - 2030 (USD Million)
  • Fig. 29 Global insects market, 2018 - 2030 (USD Million)
  • Fig. 30 Global amphibians market, 2018 - 2030 (USD Million)
  • Fig. 31 Global cell line development market: Type of cell line outlook and key takeaways
  • Fig. 32 Global cell line development market: Type of cell line movement analysis
  • Fig. 33 Global recombinant cell lines market, 2018 - 2030 (USD Million)
  • Fig. 34 Global hybridomas market, 2018 - 2030 (USD Million)
  • Fig. 35 Global continuous cell lines market, 2018 - 2030 (USD Million)
  • Fig. 36 Global primary cell lines market, 2018 - 2030 (USD Million)
  • Fig. 37 Global cell line development market: Application outlook and key takeaways
  • Fig. 38 Global cell line development market: Application movement analysis
  • Fig. 39 Global bioproduction market, 2018 - 2030 (USD Million)
  • Fig. 40 Global drug discovery market, 2018 - 2030 (USD Million)
  • Fig. 41 Global toxicity testing market, 2018 - 2030 (USD Million)
  • Fig. 42 Global tissue engineering market, 2018 - 2030 (USD Million)
  • Fig. 43 Global Others market, 2018 - 2030 (USD Million)
  • Fig. 44 Global cell line development market: Regional outlook and key takeaways
  • Fig. 45 North America cell line development market, 2018 - 2030 (USD Million)
  • Fig. 46 U.S. key country dynamics
  • Fig. 47 U.S. cell line development market, 2018 - 2030 (USD Million)
  • Fig. 48 Canada key country dynamics
  • Fig. 49 Canada cell line development market, 2018 - 2030 (USD Million)
  • Fig. 50 Europe cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Germany key country dynamics
  • Fig. 52 Germany cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 53 France key country dynamics
  • Fig. 54 France cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 55 UK key country dynamics
  • Fig. 56 UK cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 57 Italy key country dynamics
  • Fig. 58 Italy cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 59 Spain key country dynamics
  • Fig. 60 Spain cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 61 Denmark key country dynamics
  • Fig. 62 Denmark cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 63 Sweden key country dynamics
  • Fig. 64 Sweden cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 65 Norway key country dynamics
  • Fig. 66 Norway cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 67 Asia-Pacific cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 68 China key country dynamics
  • Fig. 69 China cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 70 India key country dynamics
  • Fig. 71 India cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 72 South Korea key country dynamics
  • Fig. 73 South Korea cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 74 Japan key country dynamics
  • Fig. 75 Japan cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 76 Australia key country dynamics
  • Fig. 77 Australia cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 78 Thailand key country dynamics
  • Fig. 79 Thailand cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 80 Latin America cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 81 Brazil key country dynamics
  • Fig. 82 Brazil cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 83 Mexico key country dynamics
  • Fig. 84 Mexico cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 85 Argentina key country dynamics
  • Fig. 86 Argentina cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 87 MEA cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 88 South Africa key country dynamics
  • Fig. 89 South Africa cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 90 Saudi Arabia key country dynamics
  • Fig. 91 Saudi Arabia cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 92 UAE key country dynamics
  • Fig. 93 UAE cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 94 Kuwait key country dynamics
  • Fig. 95 Kuwait cell line development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 96 Market participant categorization
  • Fig. 97 Cell line development market share analysis, 2022
  • Fig. 98 Strategy framework